Patents by Inventor Teizo Fujita
Teizo Fujita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230391889Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: January 10, 2023Publication date: December 7, 2023Inventors: Hans-Wilhelm Schwaeble, Cordula Margaret Stover, Clark E. Tedford, James Brian Parent, Teizo Fujita
-
Publication number: 20200190215Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: September 13, 2019Publication date: June 18, 2020Inventors: Hans-Wilhelm Schwaeble, Cordula Margaret Stover, Clark E. Tedford, James Brian Parent, Teizo Fujita
-
Patent number: 10660317Abstract: Genetically modified mammals are described which lack the mannan binding lectin associated serine protease MASP-2, together with methods and constructs for their production. Such mammals are useful as models for disorders of the complement system, and in the identification of treatments for such disorders. Also described are mammals which lack the associated protein MAp19; such mammals may also lack MASP-2.Type: GrantFiled: November 10, 2016Date of Patent: May 26, 2020Assignee: University of LeicesterInventors: Teizo Fujita, Hans-Wilhelm Schwaeble, Cordula Margaret Stover
-
Publication number: 20170233493Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: October 25, 2016Publication date: August 17, 2017Inventors: Hans-Wilhelm Schwaeble, Cordula Margaret Stover, Clark E. Tedford, James Brian Parent, Teizo Fujita
-
Publication number: 20170127657Abstract: Genetically modified mammals are described which lack the mannan binding lectin associated serine protease MASP-2, together with methods and constructs for their production. Such mammals are useful as models for disorders of the complement system, and in the identification of treatments for such disorders. Also described are mammals which lack the associated protein MAp19; such mammals may also lack MASP-2.Type: ApplicationFiled: November 10, 2016Publication date: May 11, 2017Inventors: Teizo Fujita, Hans-Wilhelm Schwaeble, Cordula Margaret Stover
-
Publication number: 20150067897Abstract: Genetically modified mammals are described which lack the mannan binding lectin associated serine protease MASP-2, together with methods and constructs for their production. Such mammals are useful as models for disorders of the complement system, and in the identification of treatments for such disorders. Also described are mammals which lack the associated protein MAp19; such mammals may also lack MASP-2.Type: ApplicationFiled: June 26, 2014Publication date: March 5, 2015Inventors: Teizo Fujita, Hans-Wilhelm Schwaeble, Cordula Margaret Stover
-
Patent number: 8785717Abstract: Genetically modified mammals are described which lack the mannan binding lectin associated serine protease MASP-2, together with methods and constructs for their production. Such mammals are useful as models for disorders of the complement system, and in the identification of treatments for such disorders. Also described are mammals which lack the associated protein MAp19; such mammals may also lack MASP-2.Type: GrantFiled: June 8, 2005Date of Patent: July 22, 2014Assignee: University of LeicesterInventors: Teizo Fujita, Hans-Wilhelm Schwaeble, Cordula Margaret Stover
-
Patent number: 7919094Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: GrantFiled: December 22, 2006Date of Patent: April 5, 2011Assignees: Omeros Corporation, University of LeicesterInventors: Hans-Wilhelm Schwaeble, Cordula Margaret Stover, Clark E Tedford, James B Parent, Teizo Fujita
-
Publication number: 20110020337Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: October 1, 2010Publication date: January 27, 2011Applicants: OMEROS CORPORATION, LEICESTER, UNIVERSITY OFInventors: Hans-Wilhelm Schwaeble, Cordula Margaret Stover, Clark E. Tedford, James B. Parent, Teizo Fujita
-
Publication number: 20100074899Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: September 16, 2009Publication date: March 25, 2010Applicants: OMEROS CORPORATION, LEICESTER, UNIVERSITY OFInventors: Hans-Wilhelm Schwaeble, Cordula Margaret Stover, Clark E. Tedford, James B. Parent, Teizo Fujita
-
Publication number: 20090205058Abstract: Genetically modified mammals are described which lack the mannan binding lectin associated serine protease MASP-2, together with methods and constructs for their production. Such mammals are useful as models for disorders of the complement system, and in the identification of treatments for such disorders. Also described are mammals which lack the associated protein MAp19; such mammals may also lack MASP-2.Type: ApplicationFiled: June 8, 2005Publication date: August 13, 2009Applicant: UNIVERSITY OF LEICESTERInventors: Teizo Fujita, Hans-Wilhelm Schwaeble, Cordula Margaret Stover
-
Publication number: 20070172483Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 22, 2006Publication date: July 26, 2007Applicants: Omeros Corporation, Leicester, University ofInventors: Hans-Wilhelm Schwaeble, Cordula Stover, Clark Tedford, James Parent, Teizo Fujita
-
Publication number: 20060018896Abstract: In one aspect, the invention provides methods of inhibiting the effects of lectin-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation. In some embodiments, the MAp19 inhibitory agent inhibits cellular injury associated with lectin-mediated complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides MAp19 specific antibodies that do not bind to MASP-2 and methods of producing MAp19 specific antibodies. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MAp19 inhibitory agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: June 9, 2005Publication date: January 26, 2006Applicants: University of Leicester, Omeros CorporationInventors: Hans-Wilhelm Schwaeble, Cordula Stover, Clark Tedford, James Parent, Teizo Fujita
-
Publication number: 20060002937Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASp-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: June 9, 2005Publication date: January 5, 2006Applicants: University of Leicester, Omeros CorporationInventors: Hans-Wilhelm Schwaeble, Cordula Stover, Clark Tedford, James Parent, Teizo Fujita
-
Patent number: 4630183Abstract: Disclosed is a light emitting diode lamp and a method for producing thereof, in which at least one light emitting diode is connected between at least a pair of conductive members at their upper end portions, the light emitting diode is embedded together with the conductive members in a molding of a light transmissible resin material, with the respective lower end portions of the conductive members being left exposed, and the respective exposed lower end portions of the conductive members are connected to a lamp base or cap and a contact member supported at the lower end of the lamp base or cap and insulated from the lamp base or cap.Type: GrantFiled: October 20, 1982Date of Patent: December 16, 1986Assignee: Izumi Denki CorporationInventor: Teizo Fujita
-
Patent number: 4519668Abstract: Disclosed is a wire terminal connector for use in an electric device, comprising an electrically conductive terminal plate formed with at least one screw hole, and at least one terminal screw to be screwed into the screw hole, for fixing a wire terminal between the terminal plate and the terminal screw, in which the terminal connector further comprises: a movable electrically conductive member slidably supported perpendicularly to the terminal plate, the movable member including a first portion extending parallel with the terminal plate and supporting the terminal screw, and a second portion integrally formed with the first portion and extending perpendicularly to the first portion from one end of the first portion, the second portion being formed with a rectangular stopper portion for restricting a range of movement of the first portion; a compression spring with its one end supported by the second portion of the movable member; and a fixed spring-support portion for supporting the compression spring at theType: GrantFiled: November 28, 1983Date of Patent: May 28, 1985Assignee: Idec Izumi CorporationInventors: Teizo Fujita, Yoshitaka Tsuji
-
Patent number: 4499352Abstract: Disclosed is an adapter for enabling an actuating switch, which has at least one contact section and an actuating section movably accommodating therein an actuator for actuating the contact section and which is so arranged that a first hollow cylindrical portion constituting a part of the actuating section and axially movably accommodating therein the actuator, can be directly mounted in a first hole having a first predetermined inner diameter and previously formed in a panel, to be mounted through the adapter in a second hole having a second predetermined inner diameter and previously formed in the same or another panel. The adapter comprises a first engaging device for engaging with the actuating section and a second engaging device for engaging with the panel through the second hole.Type: GrantFiled: October 26, 1982Date of Patent: February 12, 1985Assignee: Izumi Denki CorporationInventors: Teizo Fujita, Haruo Kimura
-
Patent number: 4464549Abstract: Disclosed is a digital switch which is manually rotated step by step and which comprises a casing, a wheel rotatably supported in the casing, device for manually rotating the wheel step by step, an electrical contact carried by the wheel, an electrical circuit board attached to the casing and provided with a plurality of electrical contacts which are successively touched by the electrical contact carried by the wheel when the wheel is rotated step by step, for producing an electrical signal in accordance with a stepping rotary position of the wheel, and a locking device for disabling the wheel rotating device.Type: GrantFiled: November 10, 1982Date of Patent: August 7, 1984Assignee: Idec Izumi CorporationInventor: Teizo Fujita
-
Patent number: 4427863Abstract: A small-sized relay and a method for fabricating the same are disclosed. The relay comprises a prefabricated relay mechanism and an insulating cover covering the relay mechanism. Prior to assembling the relay mechanism and cover, a laser machining device is utilized to form, in the cover, holes of very small diameter which permit flow of gas molecules therethrough but do not permit the flow of dust particles or liquid molecules therethrough. The prefabricated relay mechanism is covered with the cover formed with such holes, and the opening of the cover except the portion including the holes is closed to hermetically seal the relay mechanism.Type: GrantFiled: March 22, 1982Date of Patent: January 24, 1984Assignee: Izumi Denki CorporationInventor: Teizo Fujita
-
Patent number: D280766Type: GrantFiled: April 19, 1983Date of Patent: September 24, 1985Assignee: IDEC IZUMi CorporationInventors: Teizo Fujita, Haruo Kimura